Frontier Science and Technology Research Foundation Inc (FS) Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2018
NCT03498716
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Frontier Science and Technology Research Foundation Inc (FS) | Frontier Science Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Familial Primary Pulmonary Hypertension (Phase 3)

Hypertension (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 6